共 215 条
[11]
Rabes JP(2013)Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Circulation 128 2113-20
[12]
Allard D(2012)Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 1108-18
[13]
Ouguerram K(2012)Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins J Am Coll Cardiol 60 1888-98
[14]
Devillers M(2015)Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 1489-99
[15]
Zhang DW(2015)Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial Eur Heart J 370 1809-19
[16]
Lagace TA(2014)A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 63 2541-8
[17]
Garuti R(2014)Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2531-40
[18]
Zhao Z(2014)Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab J Am Coll Cardiol 308 2497-506
[19]
McDonald M(2012)Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 78 1073-82
[20]
Horton JD(2014)Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk–primary results from the phase 2 YUKAWA study Circ J 129 234-43